Beta-interferon in MS: effect on long-term mortality


A long-term follow-up analysis of patients enrolled in the pivotal trial of beta-interferon-1b reports that patients with relapsing-remitting MS in the active treatment arm have improved long-term mortality compared to patients in the placebo arm (Reder et al. Neurology 2010; 74: 1877-1885).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page